{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T07:12:20Z","timestamp":1743318740482,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3320-7","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T10:58:08Z","timestamp":1494413888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Kenya","family":"Kamimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8231-0883","authenticated-orcid":false,"given":"Takeshi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroteru","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Kanefuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunori","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Waguri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamagiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,10]]},"reference":[{"key":"3320_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"3320_CR2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"3320_CR3","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/cncr.28730","volume":"120","author":"ZV Fong","year":"2014","unstructured":"Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer. 2014;120:2824\u201338.","journal-title":"Cancer"},{"key":"3320_CR4","doi-asserted-by":"crossref","first-page":"10223","DOI":"10.3748\/wjg.v20.i30.10223","volume":"20","author":"P Tabrizian","year":"2014","unstructured":"Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223\u201337.","journal-title":"World J Gastroenterol"},{"key":"3320_CR5","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2009.09.004","volume":"51","author":"T Okusaka","year":"2009","unstructured":"Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2009;51:1030\u20136.","journal-title":"J Hepatol"},{"key":"3320_CR6","doi-asserted-by":"crossref","unstructured":"Kishimoto S, Miyazawa K, Terakawa Y, Ashikari H, Ohtani A, Fukushima S, et al. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 2000;91:1326\u20131332.","DOI":"10.1111\/j.1349-7006.2000.tb00921.x"},{"key":"3320_CR7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000330106","volume":"4","author":"H Nishikawa","year":"2011","unstructured":"Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, et al. A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin. Case Rep Oncol. 2011;4:327\u201335.","journal-title":"Case Rep Oncol"},{"key":"3320_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4254\/wjh.v1.i1.8","volume":"1","author":"T Ishikawa","year":"2009","unstructured":"Ishikawa T. Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World J Hepatol. 2009;1:8\u201316.","journal-title":"World J Hepatol"},{"key":"3320_CR9","first-page":"2786","volume":"13","author":"N Nagasue","year":"1986","unstructured":"Nagasue N, Yukaya H, Okamura J, Kuroda C, Kubo Y, Hirai K, et al. Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Epirubicin study Group for Hepatocellular Carcinoma. Gan To Kagaku Ryoho. 1986;13:2786\u201392.","journal-title":"Gan To Kagaku Ryoho"},{"key":"3320_CR10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1872-034X.2008.00338.x","volume":"38","author":"M Yoshikawa","year":"2008","unstructured":"Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474\u201383.","journal-title":"Hepatol Res"},{"key":"3320_CR11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00534-004-0969-5","volume":"12","author":"T Niguma","year":"2005","unstructured":"Niguma T, Mimura T, Tutui N. Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. J Hepato-Biliary-Pancreat Surg. 2005;12:249\u201353.","journal-title":"J Hepato-Biliary-Pancreat Surg"},{"key":"3320_CR12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","volume":"29","author":"M Kudo","year":"2011","unstructured":"Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339\u201364.","journal-title":"Dig Dis"},{"key":"3320_CR13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cam4.55","volume":"2","author":"A Osaki","year":"2013","unstructured":"Osaki A, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Takamura M, et al. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med. 2013;2:86\u201398.","journal-title":"Cancer Med"},{"key":"3320_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3320_CR15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1053\/j.gastro.2011.03.006","volume":"140","author":"A Villanueva","year":"2011","unstructured":"Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140:1410\u201326.","journal-title":"Gastroenterology"},{"key":"3320_CR16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2012.08.043","volume":"87","author":"J Klein","year":"2013","unstructured":"Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013;87:22\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3320_CR17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","volume":"30","author":"L Marelli","year":"2007","unstructured":"Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6\u201325.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3320_CR18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"3320_CR19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1248\/bpb.26.683","volume":"26","author":"S Kishimoto","year":"2003","unstructured":"Kishimoto S, Ohtani A, Fukuda H, Fukushima S, Takeuchi Y. Relation between intracellular accumulation and cytotoxic activity of cis-[((1R,2R)-1,2-cyclohexanediamine-N, N')bis(myristato)]platinum(II) suspended in Lipiodol. Biol Pharm Bull. 2003;26:683\u20136.","journal-title":"Biol Pharm Bull"},{"key":"3320_CR20","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/sj.bjc.6601318","volume":"89","author":"S Fujiyama","year":"2003","unstructured":"Fujiyama S, Shibata J, Maeda S, Tanaka M, Noumaru S, Sato K, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin\/lipiodol. Br J Cancer. 2003;89:1614\u20139.","journal-title":"Br J Cancer"},{"key":"3320_CR21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/MEG.0b013e3283513488","volume":"24","author":"S Yukisawa","year":"2012","unstructured":"Yukisawa S, Ishii H, Kasuga A, Matsuyama M, Kuraoka K, Takano K, et al. A transcatheter arterial chemotherapy using a novel lipophilic platinum derivative (miriplatin) for patients with small and multiple hepatocellular carcinomas. Eur J Gastroenterol Hepatol. 2012;24:583\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3320_CR22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3892\/or.2010.1011","volume":"24","author":"M Hanada","year":"2010","unstructured":"Hanada M, Takasu H, Kitaura M. Acquired resistance to miriplatin in rat hepatoma AH109A\/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis. Oncol Rep. 2010;24:1011\u20138.","journal-title":"Oncol Rep"},{"key":"3320_CR23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00270-011-0172-4","volume":"35","author":"S Watanabe","year":"2012","unstructured":"Watanabe S, Nitta N, Ohta S, Sonoda A, Otani H, Tomozawa Y, et al. Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin). Cardiovasc Intervent Radiol. 2012;35:399\u2013405.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3320_CR24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1471-230X-12-127","volume":"12","author":"K Kamimura","year":"2012","unstructured":"Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M, et al. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. BMC Gastroenterol. 2012;12:127.","journal-title":"BMC Gastroenterol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3320-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T10:58:25Z","timestamp":1494413905000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3320-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3320"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3320-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2017,5,10]]},"article-number":"322"}}